Purpose: Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic factor in P-NETs. We evaluated the efficacy of Lu-PRRT and the role of FDG PET in 60 patients with advanced P-NETs. Methods: From March 2008 to June 2011, 60 consecutive patients with P-NETs were enrolled in the study. Follow-up lasted until March 2016. Eligible patients were treated with two different total cumulative activities (18.5 or 27.8Â GBq in 5Â cycles every 6â8Â weeks), according to kidney and bone marrow parameters. Results: Twenty-eight patients received a mean full activity (FA) of 25.9Â GBq and 32 a mean reduced activity (RA) of 18.5Â GBq. The disease control rate (DCR), defined as the sum of CR+PR+SD was 85.7Â % in the FA group and 78.1Â % in the RA group. Median progression-free survival (mPFS) was 53.4Â months in the FA group and 21.7Â months in the RA group (P = 0.353). Median overall survival (mOS) was not reached (nr) in FA patients and was 63.8Â months in the RA group (P = 0.007). Fifty-five patients underwent an FDG PET scan before Lu-PRRT, 32 (58Â %) showing an increased FDG uptake in tumor sites. mPFS was 21.1Â months in FDG PET-positive patients and 68.7Â months in the FDG PET-negative group (P < 0.0002), regardless of the total activity administered. Conclusion: Both FA and RA are active in patients undergoing Lu-PRRT. However, an FA of 27.8Â GBq of Lu-PRRT prolongs PFS and OS compared to an RA of 18.5Â GBq. Our results indicate that FDG PET is an independent prognostic factor in this patient setting.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE|
|Data di pubblicazione:||2017|
|Appare nelle tipologie:||03.1 Articolo su rivista|